Article

Intracameral medication use requires careful consideration of pros and cons

When thinking about administering medications intracamerally during cataract surgery, it is important to consider whether their potential benefits are worth the risk, said Nick Mamalis, MD, at Spotlight on Cataracts 2007.

When thinking about administering medications intracamerally during cataract surgery, it is importantto consider whether their potential benefits are worth the risk, said Nick Mamalis, MD, at Spotlighton Cataracts 2007.

Intracameral medications may be used in cataract surgery for anesthesia, pupil dilation, and toprevent inflammation and endophthalmitis. Their advantages include ease of delivery, elimination oftoxicity of topical drops, avoidance of compliance issues, and possibly enhanced efficacy.

However, there are a number of downsides. Toxicity is an important risk that can occur throughmultiple mechanisms, which can be related to improper concentration, pH, or osmolarity. In addition,all medications used intracamerally should be preservative-free, but it is also important to be awareof toxicity related to stabilizing agents, such as are found in preservative-free epinephrine.Infectious contamination is another safety concern as is the potential for incompatibility whenmultiple drugs are combined.

"There are many trade-offs to consider when weighing the pros and cons of using topical drops versusintracameral medications. Intracameral medication safety can be improved if we could eliminate'kitchen pharmacy,'" Dr. Mamalis said.

"We need sterile, pre-mixed, preservative-free, unit-dose products, and the ophthalmology communityneeds to work with the FDA and industry to achieve that goal," he added.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
Barsha Lal, PhD, discusses the way low dose atropine affects accommodative amplitude and dynamics at the 2025 ARVO meeting
(Image credit: Ophthalmology Times) NeuroOp Guru: When eye findings should prompt neuroimaging in suspected neuro-Behcet disease
At the Association for Research in Vision and Ophthalmology (ARVO) meeting, Katherine Talcott, MD, a retina specialist at Cleveland Clinic, shared her findings on EYP-1901 (EyePoint Pharmaceuticals) in the phase 2 DAVIO study.
Dr. Jogin Desai, founder of Eyestem Research, discusses his research at the Association for Research in Vision and Ophthalmology.
(Image credit: Ophthalmology Times) ASCRS 2025: Michael Rivers, MD, shares his takeaways as a panelist at the inaugural SightLine event
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
John Tan talks about an emergency triage framework for retinal artery occlusion at the 2025 Association for Research in Vision and Ophthalmology (ARVO) meeting.
Dr Robert Maloney at the 2025 Controversies in Modern Eye Care meeting
Wendy Lee, MD, MS, at Controversies in Modern Eye Care 2025.
© 2025 MJH Life Sciences

All rights reserved.